Biotech Values

[DewDiligence]

ENTA’s recent strength is probably tied to the lack of FDA’s early decision for GILD’s Harvoni (PDUFA date 10/10/14). I.e., GILD’s headstart relative to ABBV/ENTA for all-oral GT1 treatment in US is likely to be small.